Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 10/20 | 0.43 |
| ▸ | F13A1 | P00488 | 2/20 | 0.43 |
| ▸ | TGM1 | P22735 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019870 | 0.89 | THRB (0.47) | THRBTHRANAMPTTGM2F13A1 | |
| SCHEMBL11511625 | 0.82 | THRA (0.61) | THRBTHRATGM2F13A1TGM1 | |
| SCHEMBL21397350 | 0.77 | HTR2C (0.49) | THRBTHRATGM2F13A1TGM1 | |
| SCHEMBL12312359 | 0.75 | THRA (0.57) | THRBTHRATGM2F13A1TGM1 | |
| SCHEMBL8867192 | 0.73 | THRA (0.65) | THRBTHRATGM2F13A1TGM1 | |
| SCHEMBL8867209 | 0.73 | THRA (0.65) | THRBTHRATGM2F13A1TGM1 | |
| Hydrochloric Acid SCHEMBL21641210 | 0.72 | HSD17B10 (0.57) | NAMPTMC4RDPP4 | |
| SCHEMBL18019652 | 0.72 | ALDH1A1 (0.46) | MC4RMEN1KMT2A | |
| SCHEMBL12265208 | 0.71 | THRA (0.63) | THRBTHRATGM2F13A1TGM1 | |
| SCHEMBL12832351 | 0.71 | THRB (0.77) | THRBTHRATGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | THRB 2244/4885THRA 1978/4885NAMPT 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.